argenx NV ADR (ARGX)vsMiMedx Group Inc (MDXG)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
MDXG
MiMedx Group Inc
$4.10
-0.73%
HEALTHCARE · Cap: $612.09M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 912% more annual revenue ($4.24B vs $418.63M). ARGX leads profitability with a 30.5% profit margin vs 11.6%. ARGX appears more attractively valued with a PEG of 0.83. MDXG earns a higher WallStSmart Score of 72/100 (B).
ARGX
Buy63
out of 100
Grade: C+
MDXG
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+65.2%
Fair Value
$14.98
Current Price
$4.10
$10.88 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Earnings expanding 99.5% YoY
Every $100 of equity generates 22 in profit
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 27.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : MDXG
The strongest argument for MDXG centers on EPS Growth, Return on Equity, P/E Ratio. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, PEG Ratio.
Key Dynamics to Monitor
MDXG carries more volatility with a beta of 1.60 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDXG scores higher overall (72/100 vs 63/100) and 27.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?